Arcadia Biosciences, Inc.
RKDANASDAQBasic Materials● Active
$0.92
$-0.15(-14.46%)
Market Cap$1416259
P/E Ratio—
52W High$6.71
52W Low$0.8
Arcadia Biosciences, Inc. (RKDA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
RKDA · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
-$2.11
Est. -$0.80 · -163.8%
Revenue
$0.00B
Est. $0.00B · -31.3%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
RKDA reports quarterly as a NASDAQ-listed Agricultural Inputs company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 19, 2026 | -$0.56 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 14, 2026 | -$0.80 | -$2.11 | -163.8% | $0.00B | $0.00B | -31.3% |
| ▼ Q1 FY2026 | Mar 26, 2026 | -$0.66 | -$0.98 | -48.5% | $0.00B | $0.00B | -35.6% |
| ▲ Q4 FY2025 | Nov 7, 2025 | -$0.54 | $0.62 | +214.8% | $0.00B | $0.00B | -31.5% |
| ▲ Q3 FY2025 | Aug 14, 2025 | -$0.79 | $0.02 | +102.5% | $0.00B | $0.00B | -33.9% |
| ▲ Q2 FY2025 | May 8, 2025 | -$0.98 | $1.90 | +293.9% | $0.00B | $0.00B | -7.7% |
| ▼ Q1 FY2025 | Mar 20, 2025 | -$0.89 | -$2.48 | -178.7% | $0.00B | $0.00B | +5.7% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -$0.77 | -$0.87 | -13.0% | $0.00B | $0.00B | +33.6% |
Q3 FY2026
Aug 19, 2026
EPS Actual
—
EPS Est.
-$0.56
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Miss
EPS Actual
-$2.11
EPS Est.
-$0.80
EPS Surpr.
-163.8%
Revenue
$0.00B
Q1 FY2026
Mar 26, 2026Miss
EPS Actual
-$0.98
EPS Est.
-$0.66
EPS Surpr.
-48.5%
Revenue
$0.00B
Q4 FY2025
Nov 7, 2025Beat
EPS Actual
$0.62
EPS Est.
-$0.54
EPS Surpr.
+214.8%
Revenue
$0.00B
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
$0.02
EPS Est.
-$0.79
EPS Surpr.
+102.5%
Revenue
$0.00B
Q2 FY2025
May 8, 2025Beat
EPS Actual
$1.90
EPS Est.
-$0.98
EPS Surpr.
+293.9%
Revenue
$0.00B
Q1 FY2025
Mar 20, 2025Miss
EPS Actual
-$2.48
EPS Est.
-$0.89
EPS Surpr.
-178.7%
Revenue
$0.00B
Q4 FY2024
Nov 12, 2024Miss
EPS Actual
-$0.87
EPS Est.
-$0.77
EPS Surpr.
-13.0%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.60 | $-0.60 | $-0.60 | 1 |
| Q3 FY2026 | $-0.46 | $-0.46 | $-0.46 | 1 |
| Q2 FY2026 | $-0.56 | $-0.56 | $-0.56 | 1 |
| Q1 FY2026 | $-0.80 | $-0.80 | $-0.80 | 1 |
| Q4 FY2025 | $-0.66 | $-0.66 | $-0.66 | 1 |
| Q3 FY2025 | $-0.54 | $-0.54 | $-0.54 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 14, 2026 | -163.8% | $1.06 | $1.07 | +0.94% |
| ▼ Q1 FY2026 | Mar 26, 2026 | -48.5% | $1.70 | $1.52 | -10.59% |
| ▲ Q4 FY2025 | Nov 7, 2025 | +214.8% | $3.90 | $3.69 | -5.38% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +102.5% | $4.63 | $4.41 | -4.75% |
| ▲ Q2 FY2025 | May 8, 2025 | +293.9% | $4.30 | $4.29 | -0.23% |
| ▼ Q1 FY2025 | Mar 20, 2025 | -178.7% | $3.44 | $3.30 | -4.07% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -13.0% | $4.24 | $4.24 | +0.00% |
| ▼ Q3 FY2024 | Aug 13, 2024 | -49.7% | $2.92 | $2.99 | +2.40% |
Q2 FY2026+0.94%
Report Date
May 14, 2026
EPS Beat/Miss
-163.8%
Price Before
$1.06
Price After
$1.07
Q1 FY2026-10.59%
Report Date
Mar 26, 2026
EPS Beat/Miss
-48.5%
Price Before
$1.70
Price After
$1.52
Q4 FY2025-5.38%
Report Date
Nov 7, 2025
EPS Beat/Miss
+214.8%
Price Before
$3.90
Price After
$3.69
Q3 FY2025-4.75%
Report Date
Aug 14, 2025
EPS Beat/Miss
+102.5%
Price Before
$4.63
Price After
$4.41
Q2 FY2025-0.23%
Report Date
May 8, 2025
EPS Beat/Miss
+293.9%
Price Before
$4.30
Price After
$4.29
Q1 FY2025-4.07%
Report Date
Mar 20, 2025
EPS Beat/Miss
-178.7%
Price Before
$3.44
Price After
$3.30
Q4 FY2024+0.00%
Report Date
Nov 12, 2024
EPS Beat/Miss
-13.0%
Price Before
$4.24
Price After
$4.24
Q3 FY2024+2.40%
Report Date
Aug 13, 2024
EPS Beat/Miss
-49.7%
Price Before
$2.92
Price After
$2.99
Avg Beat Reaction-3.45%
Avg Miss Reaction-2.26%
Beat Rate3 / 8 quarters
Largest Move-10.59% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: RKDA ends December
Arcadia Biosciences, Inc. (RKDA) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $-2.11 — missing the analyst consensus of $-0.80 by -163.8%. The next RKDA earnings date is expected around September 1, 2026.
Each quarter, investors track RKDA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. RKDA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
RKDA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
RKDA earnings · 5 questionsArcadia Biosciences, Inc.'s next earnings report is expected around September 1, 2026. RKDA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; RKDA historically reports after market close (AMC).
RKDA earnings datewhen is RKDA earningsRKDA next earnings datewhen does RKDA report earningsRKDA earnings calendar
▸ Source: FMP · Arcadia Biosciences, Inc. SEC filings · US GAAP · Arcadia Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026